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LYG for Estonia. Sensitivity analyses showed that time horizon, discounting and
follow-up cost of stroke are sensitive factors. Difference in co-payment for workers
and retired patients (Estonia) marginally impacted ICERs. Probabilistic sensitivity
analysis showed that the probability for O-3EE to be cost-effective is higher than
95% in Estonia (threshold €32,000/LYG). One-way sensitivity analyses showed
strong robustness in Ireland (threshold €20,000/QALY). CONCLUSIONS: The incre-
mental cost-effectiveness ratios indicated that adding 1g O-3EE to standard treat-
ment in secondary prevention post-MI was in the range likely to be considered
cost-effective in Ireland and Estonia.
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OBJECTIVES: To compare the incremental cost-effectiveness ratio (ICER) and in-
cremental cost-utility ratio (ICUR) of the angiotensin II receptor antagonist Azilsa-
tan vs current treatments of the same drug class as valsartan, telmisartan, losartan
and irbesartan. METHODS: Cost-effectiveness and cost-utility analysis were con-
ducted using a Markov model with a 35-year temporal horizon for patients over the
age of 45 and diagnosed with systemic arterial hypertension to calculate the ICERs
of each treatment. The model adopts the Mexican public health institutions’ per-
spective. Four health states were incorporated: alive and healthy, hypertensive
with non-fatal acute myocardial infarction (AMI), hypertensive with non-fatal
stroke and death. Transition probabilities were calculated based on the national
risk of having a stroke or AMI and the probability of having a vascular complication
depending on blood pressure levels (in mmHg). Costs and effectiveness data were
taken from health institutions, producer pharmaceutical companies or extracted
from published literature. Outcome measures included ICER and ICUR. Cost-effec-
tiveness was determined according to the 1GDP/capita threshold established by
the National Health Council in Mexico. RESULTS: Azilsartan was found to be dom-
inant when compared with telmisartan, valsartan and irbesartan. Azilsartan was
also more effective when compared with losartan (10.76 vs. 10.47 life years gained)
although more costly (USD$ 6,118.92 vs. USD$ 5,192.71). The ICER was USD$
3,202.84 per life year gained. According to the cost-utility analysis, the ICUR per
quality-adjusted life year gained was USD$ 3,458.09. CONCLUSIONS: The ICER and
ICUR are well below 1GDP (USD$ 9,350.07) per capita versus losartan. Both azilsar-
tan and losartan were found to be dominant in comparison with the other included
treatments. Azilsartan is therefore a very cost-effective intervention for the Mexi-
can population over 45 with systemic arterial hypertension.
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OBJECTIVES: Transferring cost-effectiveness information between geographic do-
mains offers the potential for more efficient use of analytical resources. However,
it is difficult for decison makers to know when they can rely on cost-effectiveness
evidence produced for another context. This paper explores the transferability of
economic evaluation results produced for one geographic area to another location
of interest, and outlines an approach to identify factors to predict when this is
appropriate. METHODS: We developed multilevel statistical models for the inte-
gration of published cost-effectiveness data to assess the impact of contextual
effects on country level; whilst controlling for baseline characteristics within, and
across, a set of economic evaluation studies. Explanatory variables were derived
from a list of factors suggested in the literature as possible constraints on the
transferability of cost-effectiveness evidence. We illustrated our approach using
published estimates of the cost-effectiveness of statins for the primary and sec-
ondary prevention of cardiovascular disease (CVD). 2094 estimates of the costs and
effects of statins were abstracted from 67 studies related to 23 geographic domains,
together with covariates on data, study and country level. RESULTS: The propor-
tion of variation at the country-level observed depends on the appropriate multi-
level model structure and never exceeds 15% for incremental effects and 21% for
incremental cost respectively. Key sources of variability are patient and disease
characteristics, intervention cost and a number of methodological characteristics
defined on the data level. There were fewer significant covariates on the study and
country levels. CONCLUSIONS: Our analysis suggests that variability in cost-effec-
tiveness data is primarily due to differences between studies, not countries. Fur-
ther, comparing different models suggests that data from multinational studies
severely underestimates country-level variability. Additional research is needed to
test the robustness of these conclusions on other sets of cost-effectiveness data,
and to further explore the appropriate set of covariates.
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OBJECTIVES: To evaluate health outcomes and costs of initiation with endothelin
receptor antagonists [ERA] monotherapy (ambrisentan or bosentan) followed by
sequential combination with phosphodiesterase-5 inhibitors [PDE-5] and prostan-
oids in the treatment of pulmonary arterial hypertension in Spain. METHODS: A
Markov model was developed based on New York Hearth Association functional
classes. Transition probabilities [TP] for ERA initiation were gathered from the
pivotal clinical trials. Outcomes were measured in quality-adjusted life years
[QALY]. A panel of 3 independent experts reached a consensus on patient manage-
ment based on clinical practice. Patients initiated treatment with either ambrisen-
tan or bosentan, and revised treatment every 12 weeks based on their health status
and previous medication records. A National Health System perspective was ad-
opted. Pharmacological costs and costs associated with very frequent adverse
events [AE] (i.e. edema and hepatic abnormalities) were included. Following a first-
order Monte Carlo simulation approach, 1,000 hypothetical patients were observed
in a temporal horizon of 60 weeks. This simulation was repeated 1,000 times.
RESULTS: Average (per-patient and year) pharmacological costs [95% CI] were
€35,550 [€34,944-€36,196] and €40,224 [€39,264-€41,212] for initiation with ambrisen-
tan and bosentan, respectively. Average costs associated with AE management
were €117 [€110-€124] and €171 [€160-€182], respectively. No clinically relevant dif-
ferences in average QALY were found: 0.6853 [0.6836-0.6870] and 0.6903 [0.6885-
0.6921], respectively. This agrees with published meta-analyses and a priori expert
judgment. Initiation with ambrisentan would bring about cost savings of €4,727
[€3,903-€5,620]. From a cost-minimization perspective, if the same TP were consid-
ered for both initiation alternatives, initiation with ambrisentan would provide
cost savings of €4,952 [€4,898-€5,007] (using ambrisentan’s TP) and €4,770 [€4,718-
€4,819] (using bosentan’s TP). CONCLUSIONS: Initiation with ambrisentan mono-
therapy followed by sequential combination with PDE-5 and prostanoids yields
comparable outcomes at lower costs than initiation with bosentan. These results
might be considered in hospital pharmacy budget allocation decision making.
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OBJECTIVES: To conduct an economic analysis of the risk assessment of VTE with
Thrombo inCode, a genetic platform, in patients with a pattern of VTE or a condi-
tion that suggests a hereditary component, compared with the standard methods
so far used (Factor V Leiden and prothrombin G20210A mutation). METHODS: A
Markov model was developed with 7 states of health (thrombophilia, no thrombo-
philia, VTE, major bleeding, intracranial hemorrhage, no intracranial hemorrhage,
and death). The predictive ability of VTE from the identification of thrombophilia
with Thrombo inCode and the standard method, was obtained from three studies
of the method validation performed in three different populations (3,661 patients
in total). It was assumed that patients with thrombophilia positively identified
undergo a preventive treatment of VTE, which involves both reducing the number
of VTE as the increase in major bleeding. The utilities and costs of Markov states
were obtained from the literature and Spanish sources. The analysis was done
from the National Health System perspective, for a time horizon of 5 years and
lifetime. An annual discount rate of 3.5% for costs and benefits was applied.
RESULTS: For a Thrombo inCode price of 290 €, this genetic platform would be the
dominant option for any time horizon from 5 years. The threshold price of
Thrombo inCode to reach the incremental cost-effectiveness ratio (ICER) threshold
generally accepted in Spain (30,000 €/QALY) would range between € 1,069 and €
1,284. Probabilistic analyses indicate that Thrombo inCode assessment is domi-
nant in the 97.2 to 98.6% of the tests, according to the selected population.
CONCLUSIONS: Thrombo inCode is a cost-effective genetic option in VTE risk as-
sessment compared with the standard method.
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OBJECTIVES: Limited pharmaceutical options are available for smoking cessation
interventions for smokers with a history of cardiovascular disease (CVD) in the
Netherlands. The objective of our study was to assess the cost-effectiveness of
varenicline versus nicotine replacement therapy (NRT) in such a population.
METHODS: A lifetime horizon Markov model was developed to compare the cost-
effectiveness of smoking cessation therapies from the health care provider per-
spective. Efficacy data (continuous abstinence rates) for each therapeutic option
was obtained from an indirect comparison of available clinical trials. The popula-
tion of smokers with cardiovascular disease was divided into three cohorts: those
with a history of coronary heart disease (CHD), stroke and peripheral vascular
disease (PVD). In the model, the cohorts are followed as they progress through
potential disease states including CHD, stroke, PVD, COPD, mouth cancer and lung
cancer. Transition probabilities depend on age (35-65, 65), gender and smoking
status (current, former or never smoker) allowing for variations in the patient
populations. Following the Dutch pharmacoeconomic research guideline, costs
and effect were discounted at 4% and 1.5%, respectively. Univariate and probabi-
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listic sensitivity analyses were performed to assess the robustness of the results.
RESULTS: The cost-effectiveness model showed a gain of 0.29 (95% CI: 0.19 - 0.40)
QALY in individuals with varenicline therapy over NRT for a 57 year old person with
CVD. Incremental costs associated with the smoking cessation program amounted
to €67 whereas incremental costs associated with additional medical costs in the
extra lifetime equalled €456 on average. In total, the incremental cost of varenicline
therapy compared to NRT was €523 (€276 - €815). Corresponding incremental cost-
effectiveness ratio was estimated at €1,817/QALY (€1171/QALY - €2440/QALY) for
varenicline vs. nicotine replacement therapy. CONCLUSIONS: The model suggests
that varenicline therapy in people with CVD is cost-effective and provides value-
for-money compared to NRT.
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OBJECTIVES: To determine the cost-effectiveness of lipid lowering therapy in the
secondary prevention of cardiovascular events in the Philippines. METHODS: A
cost-utility analysis was performed using Markov modeling in the secondary pre-
vention setting. The models incorporated efficacy of lipid lowering therapy dem-
onstrated in randomized controlled trials and mortality rates obtained from local
life tables. Average and incremental cost-effectiveness ratios (ACERs and ICERs)
were obtained for Simvastatin, Atorvastatin, Pravastatin, and Gemfibrozil. The
costs of the following were included: medications, laboratory examinations, con-
sultation (professional fees) and related expenses and production losses. The costs
were expressed in current or nominal prices as of the 1st quarter of 2010 (Philippine
peso). Utility was expressed in quality-adjusted life years gained (QALYs). Sensi-
tivity analyses were performed using variations in the cost centers, discount rates,
starting age and differences in utility weights for stroke. RESULTS: In the analysis
using the lower-priced generic counterparts, therapy using 40 mg Simvastatin
daily was the most cost-effective option compared to the other therapies, while
Pravastatin 40 mg daily was the most cost-effective alternative if the higher-priced
innovator drugs were used. In all sensitivity analyses, Gemfibrozil was strongly
dominated by the statins. CONCLUSIONS: In the secondary prevention setting,
Simvastatin or Pravastatin were the most cost-effective options compared to Ator-
vastatin and Gemfibrozil in the Philippines. Gemfibrozil was strongly dominated by
the statins.
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OBJECTIVES: To assess the cost-effectiveness of rivaroxaban versus acenocumarol
and a real-world prescription pattern (RWP), for prevention of stroke in atrial fibril-
lation (AF) patients in the Spanish NHS setting. METHODS: A Markov model was
developed with health and treatment states describing the management and con-
sequences of AF. Patients enter the model with stable non-valvular AF are treated
withoralanti-coagulantsoraRWP(53.7%patients treatedwithacenocumarol,32.6%with
acetylsalicylic acid and 13.7% untreated, data extracted from a Longitudinal Patient Data-
base) and progress between states according to transition probabilities derived from the
ROCKET-AF study (safety-on-treatment dataset), observational data and a network meta-
analysis. Costs (drug, monitoring and events costs) and outcomes were assigned to each
state, and used to estimate costs per quality-adjusted-life-year gained (QALY). A disutility
for acenocumarol was included. The cycle length was 3 months and time horizon was set
to describe the lifetime of the patients (3% annual discounting rate for costs and benefits).
A sub-population analysis compared rivaroxaban to acenocumarol in patients with poor
INR control (patients who spend less than 60% of time in therapeutic range). Probabilistic
sensitivity analysis (PSA) was conducted to test the robustness of results. RESULTS: In
base-case, drug acquisition costs were higher in rivaroxaban group (€5,117 incre-
mental cost), while cost savings were estimated for monitoring and events avoided
compared to acenocumarol group (-€2,091 and -€522, respectively) and RWP
(-€1,385 and -€2,366, respectively) with a higher effectiveness (0.20 and 0.51 incre-
mental QALYs, respectively). ICERs were €11,274/QALY vs. acenocumarol and
€3,986/QALY vs. RWP. In poor INR controlled group the ICER was €2,144/QALY. PSA
indicated a high probability of rivaroxaban being cost-effective at a threshold of
€30,000/QALY. CONCLUSIONS: In the Spanish setting rivaroxaban is a cost-effec-
tive treatment option compared to VKA in the total AF population and particularly
in poorly controlled VKA patients.
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OBJECTIVES: To estimate the cost effectiveness of rivaroxaban compared to war-
farin for the prophylaxis of stroke in patients with atrial fibrillation (AF) from a
payer perspective in Slovakia. METHODS: A Markov model based on the results of
a large double-blind, randomized controlled clinical trial (ROCKET AF) has been
developed and adapted to the Slovakian settings. The model consists of health
states covering the management and outcomes of AF. Costs and utilities were
assigned to each state as well as to the warfarin therapy to reflect the burden of this
therapy (regular INR monitoring, dietary restrictions). Local cost data were based
on published local data, official price lists, clinical guidelines and product labels.
Data for utilities were derived from literature. The time horizon reflected a pa-
tient’s life-time. To estimate the incremental costs per quality-adjusted life year
gained (ICER) a discount rate of 5% was applied to costs and effects according to
official guidelines. One-way and probabilistic sensitivity analyses were performed.
RESULTS: Rivaroxaban was cost-effective compared to warfarin with an ICER of
17.432 € (incremental QALYs of 0,22 and incremental costs of 3 835 €). The one-way
and probabilistic sensitivity analyses indicated that these results are fairly robust
for most parameters and that rivaroxaban is cost-effective in the majority of
simulations. CONCLUSIONS: Prevention of stroke with rivaroxaban in population
of AF patients is cost-effective when compared to warfarin in the Slovakian setting.
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OBJECTIVES: To conduct an economic analysis of the risk assessment of ischemic
heart disease (IHD) with Cardio inCode (adding the genetic risk to the functions of
REGICOR and Framingham) compared with the standard method (using only the
functions).METHODS:A Markov model was developed with 7 states of health (low,
intermediate, high IHD risk; IHD event, recurrent IHD, chronic IHD and death). The
reclassification of IHD risk derived from genetic information and transition prob-
abilities between states were obtained from a validation study conducted in co-
horts of REGICOR (Spain) and Framingham (USA). It was assumed that patients
classified as intermediate risk by the standard method could be evaluated and their
risk reclassified with Cardio inCode. The utilities and costs of Markov states were
obtained from the literature and Spanish sources. The analysis was done from the
perspective of the National Health System, for a time-life horizon. An annual dis-
count rate of 3.5% for costs and benefits was applied. RESULTS: For a Cardio inCode
price of 400 €, the cost per quality-adjusted life year (QALY) gained compared with
the standard method (incremental cost effectiveness ratio, ICER) would be € 12,957
and € 21,328 in REGICOR and Framingham cohorts, respectively. The threshold
price of Cardio inCode to reach the ICER threshold generally accepted in Spain
(30,000 €/QALY) would range between € 668 and € 836. The greatest benefit occurred
in the subgroup of patients with intermediate-high risk, with a high risk reclassi-
fication of 22.8% of patients and an ICER of € 1,650/QALY and € 5,893/QALY (REGI-
COR and Framingham cohorts). Sensitivity analyses confirmed the stability of the
study results. CONCLUSIONS: Cardio inCode is a cost-effective genetic option in
IHD risk assessment compared with the standard method.
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OBJECTIVES: To combine and supplement public national registries and patient
level chart data in order to describe and compare demographics, treatment pat-
terns and mortality in patients with chronic thromboembolic pulmonary hyper-
tension (CTEPH), a rare disease. METHODS: Using the national Swedish prescrip-
tion, inpatient and cause of death registries, CTEPH patients were identified via
algorithms about drug prescriptions and diagnostic/procedural codes. A second
cohort, identified from medical charts of diagnosed CTEPH patients treated in spe-
cialized treatment centers across five European countries was abstracted retro-
spectively. Descriptive statistics and potential areas of complementary informa-
tion are described. RESULTS: Basic data on demographic and clinical
characteristics, medication and selected health resource consumption data were
found to have sufficient overlap to allow the comparison between cohorts. From
Swedish registries, 94 CTEPH patients were identified. In the medical charts, 116
patients were included. Mean age of 61.414.5 years in registry patients was 6.1
years younger than the chart cohort (67.512.3). Both cohorts were predominantly
female (registry 52%, chart cohort 61%). Medications for pulmonary arterial hyper-
tension were common in both datasets: endothelin receptor antagonists were 45%
in registry versus 60% in chart, followed by phosphodiesterase-5 inhibitors (regis-
try 36%, chart 32%), and prostacyclins were less common (5-6%). Concomitant
medications had similar patterns in both cohorts, as anticoagulants and diuretics
were most frequently prescribed (registry 64%, 43%; chart 60%, 41%). Annualized
mortality rate was slightly higher in the registry (9.9%) compared to the chart
cohort (8.2%). Additional and complementary information was provided from chart
abstraction, including: Frequency of outpatient visits, medical procedures/exami-
nations and detailed clinical outcomes.CONCLUSIONS:Despite differences in data
sources, these cohorts showed overall similarity in demographic characteristics,
treatment patterns and clinical results. This approach supports the ability of sup-
plementing nationally available register data with patient level data in order to
broadly describe the burden of rare diseases like CTEPH.
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